Investing.com -- Roche Holding AG (SIX:RO) on Tuesday announced positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity. The drug achieved 22.5% ...
A late-stage trial program of CT-388 is expected to start this quarter.
Coming up on the Redmond Patch calendar: FREE Sip And Ask Home Buying And Selling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results